Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis